Chapter/Section Purchase

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Instrument
1.2.3 Reagents and Consumables
1.2.4 Others
1.3 Market by Application
1.3.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Tumor
1.3.3 Diabetes
1.3.4 Mental Diseases
1.3.5 Cardiovascular Diseases
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Perspective (2017-2028)
2.2 Pharmacogenomics Technology (Theranostics & CDx) Growth Trends by Region
2.2.1 Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Region (2017-2022)
2.2.3 Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Region (2023-2028)
2.3 Pharmacogenomics Technology (Theranostics & CDx) Market Dynamics
2.3.1 Pharmacogenomics Technology (Theranostics & CDx) Industry Trends
2.3.2 Pharmacogenomics Technology (Theranostics & CDx) Market Drivers
2.3.3 Pharmacogenomics Technology (Theranostics & CDx) Market Challenges
2.3.4 Pharmacogenomics Technology (Theranostics & CDx) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmacogenomics Technology (Theranostics & CDx) Players by Revenue
3.1.1 Global Top Pharmacogenomics Technology (Theranostics & CDx) Players by Revenue (2017-2022)
3.1.2 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Players (2017-2022)
3.2 Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pharmacogenomics Technology (Theranostics & CDx) Revenue
3.4 Global Pharmacogenomics Technology (Theranostics & CDx) Market Concentration Ratio
3.4.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmacogenomics Technology (Theranostics & CDx) Revenue in 2021
3.5 Pharmacogenomics Technology (Theranostics & CDx) Key Players Head office and Area Served
3.6 Key Players Pharmacogenomics Technology (Theranostics & CDx) Product Solution and Service
3.7 Date of Enter into Pharmacogenomics Technology (Theranostics & CDx) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmacogenomics Technology (Theranostics & CDx) Breakdown Data by Type
4.1 Global Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Type (2017-2022)
4.2 Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Type (2023-2028)
5 Pharmacogenomics Technology (Theranostics & CDx) Breakdown Data by Application
5.1 Global Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Application (2017-2022)
5.2 Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size (2017-2028)
6.2 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type
6.2.1 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2017-2022)
6.2.2 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2023-2028)
6.2.3 North America Pharmacogenomics Technology (Theranostics & CDx) Market Share by Type (2017-2028)
6.3 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application
6.3.1 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2017-2022)
6.3.2 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2023-2028)
6.3.3 North America Pharmacogenomics Technology (Theranostics & CDx) Market Share by Application (2017-2028)
6.4 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country
6.4.1 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2017-2022)
6.4.2 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size (2017-2028)
7.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type
7.2.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2017-2022)
7.2.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2023-2028)
7.2.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Share by Type (2017-2028)
7.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application
7.3.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2017-2022)
7.3.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2023-2028)
7.3.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Share by Application (2017-2028)
7.4 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country
7.4.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2017-2022)
7.4.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size (2017-2028)
8.2 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type
8.2.1 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Share by Type (2017-2028)
8.3 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application
8.3.1 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Share by Application (2017-2028)
8.4 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region
8.4.1 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size (2017-2028)
9.2 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type
9.2.1 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2017-2022)
9.2.2 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2023-2028)
9.2.3 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Share by Type (2017-2028)
9.3 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application
9.3.1 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2017-2022)
9.3.2 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2023-2028)
9.3.3 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Share by Application (2017-2028)
9.4 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country
9.4.1 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2017-2022)
9.4.2 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size (2017-2028)
10.2 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type
10.2.1 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Share by Type (2017-2028)
10.3 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application
10.3.1 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Share by Application (2017-2028)
10.4 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country
10.4.1 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Illumina
11.1.1 Illumina Company Details
11.1.2 Illumina Business Overview
11.1.3 Illumina Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.1.4 Illumina Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.1.5 Illumina Recent Developments
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.2.4 Roche Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.2.5 Roche Recent Developments
11.3 Agilent
11.3.1 Agilent Company Details
11.3.2 Agilent Business Overview
11.3.3 Agilent Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.3.4 Agilent Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.3.5 Agilent Recent Developments
11.4 Abbott
11.4.1 Abbott Company Details
11.4.2 Abbott Business Overview
11.4.3 Abbott Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.4.4 Abbott Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.4.5 Abbott Recent Developments
11.5 Thermofisher
11.5.1 Thermofisher Company Details
11.5.2 Thermofisher Business Overview
11.5.3 Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.5.4 Thermofisher Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.5.5 Thermofisher Recent Developments
11.6 Qiagen
11.6.1 Qiagen Company Details
11.6.2 Qiagen Business Overview
11.6.3 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.6.4 Qiagen Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.6.5 Qiagen Recent Developments
11.7 Guardant Health
11.7.1 Guardant Health Company Details
11.7.2 Guardant Health Business Overview
11.7.3 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.7.4 Guardant Health Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.7.5 Guardant Health Recent Developments
11.8 MGI Tech Co., Ltd.
11.8.1 MGI Tech Co., Ltd. Company Details
11.8.2 MGI Tech Co., Ltd. Business Overview
11.8.3 MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.8.4 MGI Tech Co., Ltd. Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.8.5 MGI Tech Co., Ltd. Recent Developments
11.9 Amoydx Biology
11.9.1 Amoydx Biology Company Details
11.9.2 Amoydx Biology Business Overview
11.9.3 Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.9.4 Amoydx Biology Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.9.5 Amoydx Biology Recent Developments
11.10 Genomics
11.10.1 Genomics Company Details
11.10.2 Genomics Business Overview
11.10.3 Genomics Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.10.4 Genomics Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.10.5 Genomics Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer